COVID-19-ASSOCIATED IMMUNE THROMBOCYTOPENIA

• Main Authors: Mara-Andrada Plesu, Gabriel Cristian Bejan, Ioana Veronica Grajdeanu, Anca Angela Simionescu, Ana Maria Alexandra Stănescu
• Format: Article
• Language: English
• Published: Amaltea Medical Publishing House 2021-06-01
• Series: Romanian Journal of Infectious Diseases
• Subjects: thrombocytopenia; immune thrombocytopenic purpura; covid-19; sars-cov-2; coronavirus
• Online Access: https://rjid.com.ro/articles/2021.2/RJID_2021_2_Art-01.pdf

The coronavirus disease 2019 (COVID-19) is a contagious respiratory tract infection caused by the betacoronavirus SARS-CoV-2. The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020. Since the COVID-19 pandemic started, more than 166 million patients have been tested positive worldwide with more than 3.4 million related death recorded. COVID-19 has a wide range of signs and symptoms. Hematological changes such as lymphopenia, thrombocytopenia, and coagulation disturbances are not unusual in patients with COVID-19. However, the mechanisms causing these changes are partially comprehended. Immune thrombocytopenia was identified to be among the hematologic autoimmune diseases seen in patients infected with SARS-CoV-2. This review summarizes the evidence on COVID-19-associated immune thrombocytopenia and the underlying mechanisms involved in its development.